[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"deprescribing\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:deprescribing":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,53,80,114],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":33,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100498084","effectiveness-of-a-joint-general-practitioner-pharmacist-intervention-on-benzodiazepine-deprescribing-in-the-elderly-100498084",false,"NCT05765656","Effectiveness of a Joint General Practitioner-Pharmacist Intervention on Benzodiazepine Deprescribing in the Elderly","Evaluation of the Effectiveness of a Joint General Practitioner-Pharmacist Intervention on the Implementation of Benzodiazepine Deprescribing in the Elderly (BESTOPH-MG Trial): Protocol for a Cluster-randomized Controlled Trial","BESTOPH-MG","Inclusion Criteria:\n\n* outpatients aged 65 and over\n* followed by the general practitioner and the pharmacist of the GP-PO pair\n* having a prescription for an anxiolytic or hypnotic BZDR prescribed at least 4 times in the past year\n* the last prescription being less than 3 months old\n* having been dispensed monthly during the last 3 months\n* affiliated to a social security scheme\n* and having given consent to participate in the research.\n\nExclusion Criteria:\n\n* patients living in an institution\n* participating in a clinical trial\n* with epilepsy\n* active depression\n* uncontrolled mental disorders\n* unable to participate in an interview or answer a questionnaire (demented, non-French speaking, illiterate, deaf, ...)\n* under guardianship\n* with a dystonic syndrome\n* and patients who are not sufficiently autonomous to carry out the steps inherent in the study","ALL","65 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","Benzodiazepines or related drug (BZDR) are consumed for hypnotic or anxiolytic purposes in most cases. The consequences of BZDR are multiple with an increased risk of daytime sedation, balance disorders leading to falls and fractures, cognitive disorders, road accidents and dementia. Given their comorbidities, physiological changes, and multiple medications, the elderly are more at risk of suffering from BZDR adverse events.\n\nInterprofessional collaboration has shown efficacy in improving prescribing appropriateness and may affect patients outcomes positively. Morever, motivational interviews (MI) may reduce the extent of substance abuse compared to no intervention.",[27,28,29,30,31,32],"Primary Care","Health Plan Implementation","Benzodiazepine Dependence","Elderly","Anxiety","Deprescribing",[34,35,36,37,38,39],"Primary care","collaborative practice","health plan implementation","deprescribing","benzodiazepine","elderly","RECRUITING","2026-06-19",{"date":43,"type":44},"2026-06-24","ACTUAL",{"date":46,"type":44},"2023-10-16",{"date":48,"type":21},"2027-02-16",{"name":50,"class":51},"Nantes University Hospital","OTHER",1,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":4,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},"100530922","deprescribing-perceptions-of-patients-living-with-advanced-cancer-100530922","NCT06193083","DEprescribing: Perceptions of PAtients Living With Advanced Cancer","DEprescribing: Perceptions of PAtients Living With Advanced Cancer. A Multicentre, Prospective Mixed Observational Study","DEPAL","Inclusion Criteria:\n\n* Patient over 18 years of age\n* Locally advanced or metastatic solid cancer (i.e., palliative care as defined by the World Health Organization)\n* Life expectancy estimated by the physician at inclusion of less than 1 year (use of surprise question to help clinician estimate life expectancy)\n* Hospitalized or in consultation\n* With at least one PIMs (identified using STOPPfrail 2)\n* Patient not having expressed opposition to participating in the study after receiving information from the physician.\n\nFor qualitative study patients :\n\n\\- Patients who have signed an authorization for the recording of their voice during the semi-structured interview for the purpose of written transcription.\n\nExclusion Criteria:\n\n* Minor\n* Major under guardianship, protected person\n* Patient unable to speak or write French\n* Patient with impaired judgment, cognitive or sensory impairment that prevents him\u002Fher from receiving informed information, answering questionnaires or participating in a study interview.","18 Years",{"count":63,"type":21},325,"OBSERVATIONAL","Polymedication in palliative oncology care is a real public health problem. This phenomenon has been shown to increase the risk of iatrogenesis, reduce patients' quality of life and increase healthcare costs. For many years, health policies have been developed in geriatrics to reduce polymedication through deprescription tools.\n\nRecently, palliative care initiatives have been introduced, but without having studied the potential specificities of this population (younger, with a different care dynamic and life trajectory). It is important to better understand this population's perceptions of deprescribing in order to adapt tools\u002Factions to make these approaches more efficient.\n\nThe primary aim of this study is to investigate patients' perceptions of deprescribing in palliative cancer care, and the secondary aim is to investigate factors that may influence patients' attitudes and beliefs about deprescribing. At the same time, we will study the psychometric properties of the rPATD (Revised Patients' Attitudes Towards Deprescribing) in this population (a standardized questionnaire validated in geriatric medicine to assess patients' perceptions of deprescription).An ancillary study will be carried out to investigate the link between patients' health literacy and their perception of deprescribing (health literacy is defined as the ability to acquire, understand and use information in ways that promote and maintain good health).\n\nTo meet our objectives, we will conduct a 3-year national, prospective, observational, multicenter study with an exploratory sequential mixed design. The study will comprise an initial qualitative phase. Semi-directed individual interviews using a descriptive approach will be carried out (around 25 patients, over an 8-month period). Following analysis of the qualitative data, we will then carry out a quantitative study to determine the distribution of the different profiles within this population and the factors influencing the perception of deprescription. The self-administered questionnaires, rPATD and BMQ (medication beliefs questionnaire), potentially supplemented by other items following analysis of the qualitative data, will be administered to 300 patients (over a 12-month period).The ancillary study will be carried out during this second phase, using a validated self-questionnaire to assess patients' level of literacy.\n\nThanks to the different results, we will improve our knowledge of the perception of deprescription in palliative oncology care, in order to develop approaches adapted to the specificities of our population to reduce polymedication and thus improve the quality of life of our patients and reduce the risks of iatrogenia.",[32,67,68],"Palliative Care","Oncology",[32,70,68],"Palliative care","2026-02-09",{"date":73,"type":44},"2026-02-11",{"date":75,"type":44},"2024-02-28",{"date":77,"type":21},"2026-12-29",{"name":50,"class":51},8,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":96,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":4},"100623547","general-practitioner--pharmacist-support-for-discontinuing-long-term-antidepressants-in-clinically-stable-patients-100623547","NCT07398053","General Practitioner & Pharmacist Support for Discontinuing Long-term Antidepressants in Clinically Stable Patients","General Practitioner & Pharmacist Support for Discontinuing Long-term Antidepressants in Clinically Stable Patients: a Cluster Randomised Pragmatic Trial in Primary Care","GPS-AD","Inclusion Criteria:\n\nPatients will be eligible for inclusion in the study if they meet all of the following criteria:\n\n* Are 18 years or older and capable of providing informed consent.\n* Have their Global Medical File (GMD) managed by one of the participating GPs.\n* Have been prescribed AD (any type) by their GP for the treatment of depression, with:\n\n  * at least 6 months of continuous daily use following a first depressive episode, or\n  * at least 2 years of continuous daily use in the context of a relapsed depression\u002Frecurrent episode\n* Are judged by their GP as no longer meeting the criteria for a current depressive disorder.\n\nExclusion Criteria:\n\nPatients will be excluded from participation in the study if they meet any of the following criteria:\n\n* AD discontinuation is considered contra-indicated by the treating GP.\n* The patient is judged by the GP to be at high risk of relapse. This includes any of the following:\n\n  * Current significant depressive symptoms, defined as a score of ≥12 on the PHQ-9\n  * Current significant anxiety symptoms, defined as a score of ≥10 on the Generalised Anxiety Disorder-7 (GAD-7) scale.\n  * Current suicidal ideation, defined as a score \\>0 on item 9 (suicidality) of the PHQ-9.\n  * The patient is currently receiving only psychiatric treatment (out- or inpatient) for depression\n\nIn addition to the criteria increasing the risk of relapse, the following will also be an exclusion criteria:\n\n* The patient has a current psychiatric comorbidity (e.g. bipolar disorder, psychosis, substance use)\n* The patient has a diagnosis of dementia or significant cognitive impairment (assessed by GP judgement) or is living in a nursing home.\n* The AD is prescribed for a primary indication other than depression, such as anxiety alone without comorbid depressive disorder, or chronic pain.\n* The patient has insufficient language proficiency in Dutch or French to participate in the study procedures (e.g. providing consent, completion of questionnaires, interviews).\n* use of trazodon as AD as this is mainly used for sleep problems",{"count":89,"type":21},324,[24],"In Belgium, many adults who have suffered from depression keep using antidepressants on a daily basis for years afterwards, sometimes longer than guidelines recommend. Yet for some people who have been feeling well for a long time, this is no longer necessary, while the continued use of antidepressants can lead to side effects and causes additional costs for the healthcare system.\n\nHowever, reducing the doses of antidepressants or stopping altogether is not always easy. Some patients are afraid that their depression will return, and GPs and pharmacists often find the subject difficult to broach.\n\nThis is why the GPS-AD study is investigating a new approach in which GPs and pharmacists work more closely together to provide better support to patients. First, the GP invites patients who have been taking antidepressants for a long time for a consultation. Together, they discuss whether tapering of the medication is reasonable and feasible. If they agree to stop the treatment, the GP draws up a tapering plan tailored to the patient. The pharmacist helps monitor this process, offering advice and support to the patient while the doses are gradually reduced.\n\nThe study will extend over a period of two years and will take place in GP practices throughout Belgium. The new approach based on closer collaboration between GPs and pharmacists will be compared to the current standard of care, to determine whether it helps more long-term users to stop taking antidepressants without experiencing a recurrence of depressive symptoms.\n\nThe name of the study, GPS-AD (General Practitioner and Pharmacist Support for Antidepressant Discontinuation), refers to the collaboration between GPs and pharmacists in tapering of antidepressants, and also symbolises the support and guidance (the 'GPS') provided to patients and healthcare providers in assessing whether long-term use of antidepressants is still necessary.",[32,93,94,95,27],"Antidepressant","Depression Disorder","Discontinuation",[37,97,98,99,100,101,102,103,104],"discontinuation","tapering","depression","antidepressants","long-term use","chronic use","medication review","primary care","NOT_YET_RECRUITING","2026-02-02",{"date":71,"type":44},{"date":109,"type":21},"2026-03-01",{"date":111,"type":21},"2028-05-31",{"name":113,"class":51},"University Ghent",{"id":115,"slug":116,"hasResults":11,"nctId":117,"briefTitle":118,"officialTitle":119,"acronym":4,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":52},"100582059","rak-pride-optimizing-proton-pump-inhibitor-use-through-education-and-intervention-100582059","NCT06858384","RAK-PRIDE: Optimizing Proton Pump Inhibitor Use Through Education and Intervention","From Awareness to Action: Transforming Proton Pump Inhibitor Use in Ras Al Khaimah Through Education and Intervention: the RAK -PRIDE Study","Inclusion Criteria:\n\nPhysicians will be eligible to participate if:\n\n* They are prescribing PPIs in outpatient department of the study sites\n* They have patients with potentially inappropriate PPI prescriptions\n\nPatients will be eligible to participate if:\n\n* They are ≥18 years\n* They are presenting to out-patient departments of the study sites\n* They have prescriptions of potentially inappropriate PPIs\n* Their treating physicians are included in the study\n\nExclusion Criteria:\n\nPhysicians will be excluded if:\n\n• They are involved in any other prescribing trial\n\nPatients will be excluded if:\n\n* They are unable to give informed consent, as judged by their physicians\n* They have definitive indications for PPI use",{"count":122,"type":21},479,[24],"The goal of this study is to determine if a pharmacist-led educational intervention can reduce the inappropriate use of proton pump inhibitors (PPIs) among adult patients (≥18 years) with potentially inappropriate PPI prescriptions in Ras Al Khaimah.\n\nThe main questions it aims to answer are:\n\n* Can a pharmacist-led education program reduce unnecessary PPI use?\n* Does the intervention improve patients' quality of life and reduce healthcare costs? Researchers will compare the intervention group (receiving pharmacist-led education and materials) to the usual care group to see if the intervention reduces PPI use and improves patient outcomes.\n\nParticipants will:\n\n* Receive educational materials from pharmacists, including a patient educational brochure, PPI patient decision aid, PPI deprescribing pamphlet, and PPI patient action plan.\n* Physicians involved will also receive a pharmaceutical intervention, which includes a physician educational brochure, PPI evidence-based deprescribing guideline, PPI deprescribing algorithm, and whiteboard videos on PPI deprescribing.\n* Patients will be followed up for 6 months to monitor changes in PPI use, symptoms, and quality of life.",[126,32,127],"Proton Pump Inhibitors","Inappropriate Use",[129,130,32,131,132,133],"proton pump inhibitors","peptic ulcer disease","pharmacist-led educational intervention","inappropriate use","RAK - PRIDE","2025-03-08",{"date":136,"type":44},"2025-03-12",{"date":138,"type":21},"2025-03",{"date":140,"type":21},"2026-02",{"name":142,"class":51},"RAK Medical and Health Sciences University"]